Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment
Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike...
SHA: 600566
Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing...
Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co.,...